667P - Altered expression of cMET and PIK3CA are associated with primary gastric cancer

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Gastric Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Tania Fleitas
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors T. Fleitas1, M. Ibarrola-Villava2, N. Tarazona1, R. Cervera3, C. Mongort3, S. Navarro3, S. Rosello4, G. Ribas1, J.A. Pérez-Fidalgo1, A. Cervantes Ruiperez1
  • 1Medical Oncology And Hematology Unit, Health Research Institute INCLIVA, 46010 - Valencia/ES
  • 2Medical Oncology And Hematology Unit, , Health Research Institute INCLIVA, 46010 - Valencia/ES
  • 3Pathology Unit, Hospital Clinico Universitario, 46010 - Valencia/ES
  • 4Serv. Hematologia Y Oncologia Medica, Hospital Clinico Universitario de Valencia, ES-46010 - Valencia/ES



Gene expression analysis has gained interest as a tool for classifying gastric cancer. We studied patterns of expression of ARID1A, CDH1, cMET and PIK3CA in primary gastric tumors. A correlation of these genes with HER2 and HER3 was also analyzed.


A retrospective case-control study was done with normal gastric tissue as control. Real-time-quantitative PCR was used to examine gene expression. HER2 and HER3 status were determined by immunohistochemistry.


48 gastric patients were recruited of whom 22 had normal gastric tissue available. cMET and PIK3CA were significantly overexpressed in tumor versus normal tissue. ARID1A and CDH1 expression showed no differences. In tumor tissue, expression of cMET and PIK3CA were inversely correlated with ARID1A (Odds ratio (OR)= 0.52, p = 0.002 and OR = 0.45, p = 0.008 respectively), as well as cMET and CDH1 (OR = 0.59, p < 0.001). HER2 and HER3 overexpression were not correlated with either of these genes.


cMET and PIK3CA genes are overexpressed in gastric tumors independently of HER2 and HER3 overexpression. *Dr. Ibarrola-Villava M. contributed equally to this work as the presenter author. **Dr. Tarazona N.is currently working at the Gastrointestinal Cancer Unit of the Royal Marsden Hospital as an ESMO Traslational Reasearch Fellow.


All authors have declared no conflicts of interest.